Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 4
2012 4
2013 2
2014 1
2015 2
2016 3
2020 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean germline i. Coward (1 results)?
Mucinous ovarian cancer: A therapeutic review.
Xu W, Rush J, Rickett K, Coward JI. Xu W, et al. Crit Rev Oncol Hematol. 2016 Jun;102:26-36. doi: 10.1016/j.critrevonc.2016.03.015. Epub 2016 Mar 19. Crit Rev Oncol Hematol. 2016. PMID: 27083591 Review.
The role of interleukin-6 in malignant mesothelioma.
Abdul Rahim SN, Ho GY, Coward JI. Abdul Rahim SN, et al. Transl Lung Cancer Res. 2015 Feb;4(1):55-66. doi: 10.3978/j.issn.2218-6751.2014.07.01. Transl Lung Cancer Res. 2015. PMID: 25806346 Free PMC article. Review.
Chemotherapy advances in small-cell lung cancer.
Chan BA, Coward JI. Chan BA, et al. J Thorac Dis. 2013 Oct;5 Suppl 5(Suppl 5):S565-78. doi: 10.3978/j.issn.2072-1439.2013.07.43. J Thorac Dis. 2013. PMID: 24163749 Free PMC article. Review.
The role of interleukin-6 in gynaecological malignancies.
Coward JI, Kulbe H. Coward JI, et al. Cytokine Growth Factor Rev. 2012 Dec;23(6):333-42. doi: 10.1016/j.cytogfr.2012.08.005. Epub 2012 Sep 30. Cytokine Growth Factor Rev. 2012. PMID: 23031497 Review.
Interleukin-6: an angiogenic target in solid tumours.
Middleton K, Jones J, Lwin Z, Coward JI. Middleton K, et al. Crit Rev Oncol Hematol. 2014 Jan;89(1):129-39. doi: 10.1016/j.critrevonc.2013.08.004. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24029605 Review.
Rethinking ovarian cancer: recommendations for improving outcomes.
Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Vaughan S, et al. Among authors: coward ji. Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144. Nat Rev Cancer. 2011. PMID: 21941283 Free PMC article.
New perspectives on targeted therapy in ovarian cancer.
Coward JI, Middleton K, Murphy F. Coward JI, et al. Int J Womens Health. 2015 Feb 4;7:189-203. doi: 10.2147/IJWH.S52379. eCollection 2015. Int J Womens Health. 2015. PMID: 25678824 Free PMC article. Review.
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results.
Coward JI, Barve MA, Kichenadasse G, Moore KN, Harnett PR, Berg D, Garner JS, Dizon DS. Coward JI, et al. Cancers (Basel). 2021 Jun 26;13(13):3196. doi: 10.3390/cancers13133196. Cancers (Basel). 2021. PMID: 34206826 Free PMC article.
15 results